MaxCyte Upgraded to Strong Buy What Does It Mean for the Stock?
| MXCT Stock | USD 3.62 0.15 3.98% |
Slightly above 62% of MaxCyte's investor base is looking to short. The analysis of overall sentiment of trading MaxCyte stock suggests that many investors are alarmed at this time. MaxCyte's investing sentiment can be driven by a variety of factors including economic data, MaxCyte's earnings reports, geopolitical events, and overall market trends.
MaxCyte |
MaxCyte might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 .
Read at zacks.com
 |
MaxCyte Fundamental Analysis
We analyze MaxCyte's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of MaxCyte using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of MaxCyte based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Asset
Net Asset Comparative Analysis
MaxCyte is currently under evaluation in net asset category among its peers. Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
MaxCyte Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with MaxCyte stock to make a market-neutral strategy. Peer analysis of MaxCyte could also be used in its relative valuation, which is a method of valuing MaxCyte by comparing valuation metrics with similar companies.
Peers
MaxCyte Related Equities
| SGHT | Sight Sciences | 12.85 | ||||
| LUNG | Pulmonx Corp | 6.22 | ||||
| CVRX | CVRx | 3.56 | ||||
| IRMD | Iradimed | 2.00 | ||||
| SRDX | SurModics | 1.01 | ||||
| KIDS | Orthopediatrics Corp | 0.22 | ||||
| ANIK | Anika Therapeutics | 0.11 | ||||
| ITGR | Integer Holdings | 1.15 | ||||
| OFIX | Orthofix Medical | 1.43 | ||||
| CNMD | CONMED | 2.10 | ||||
| NPCE | Neuropace | 2.60 | ||||
| RPID | Rapid Micro | 3.90 |
Additional Tools for MaxCyte Stock Analysis
When running MaxCyte's price analysis, check to measure MaxCyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MaxCyte is operating at the current time. Most of MaxCyte's value examination focuses on studying past and present price action to predict the probability of MaxCyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MaxCyte's price. Additionally, you may evaluate how the addition of MaxCyte to your portfolios can decrease your overall portfolio volatility.